secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0000950170-25-011220
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome receives FDA approval for SYMBRAVO (meloxicam/rizatriptan) for acute migraine in adults
--------------------------------------------------------------------------------

- SYMBRAVO approved by FDA for acute treatment of migraine; expected commercially available in ~4 months.
- In MOMENTUM trial, 77% of patients did not require rescue medication within 24h; superior to rizatriptan on sustained pain freedom.
- In INTERCEPT trial (mild pain), 85% of patients did not require rescue medication within 24h; pain freedom sustained through 24-48h.
- Most common adverse reactions: somnolence and dizziness (2% vs 1%). Long-term safety from MOVEMENT trial over 12 months.
- Patented MoSEIC technology provides 5x faster meloxicam absorption; patent protection through at least 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/0000950170-25-011220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-20250130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-011220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer